Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
934.27B
Market cap934.27B
Price-Earnings ratio
42.84
Price-Earnings ratio42.84
Dividend yield
0.63%
Dividend yield0.63%
Average volume
3.20M
Average volume3.20M
High today
$991.20
High today$991.20
Low today
$966.09
Low today$966.09
Open price
$972.05
Open price$972.05
Volume
2.62M
Volume2.62M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

The current Eli Lilly(LLY) stock price is $990.00, with a market capitalization of 934.27B. The stock trades at a price-to-earnings (P/E) ratio of 42.84 and offers a dividend yield of 63.4%.

As of 2026-03-06, Eli Lilly(LLY) stock has fluctuated between $966.09 and $991.20. The current price stands at $990.00, placing the stock +2.5% above today's low and -0.1% off the high.

Eli Lilly(LLY) shares are trading with a volume of 2.62M, against a daily average of 3.2M.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.

LLY News

TipRanks 8h
GoodRx to team with Eli Lilly to expand employer-sponsored access to Zepbound

GoodRx (GDRX) announced employer-sponsored access to Zepbound KwikPen through GoodRx Employer Direct. As one of Eli Lilly’s (LLY) Employer Connect independent p...

TipRanks 1d
Eli Lilly’s Abemaciclib Combo Pushes Deeper Into Advanced Prostate Cancer

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 1b study “A Phase 1b Study of Abemaciclib Plus Darolutamide in Men W...

TipRanks 1d
Your Boss May Soon Cover the Cost of Obesity Drugs. Here’s Eli Lilly’s Plan

U.S. pharmaceutical giant Eli Lilly (LLY) has launched a new program designed to help more employers cover the cost of weight-loss medications. Currently, a la...

Analyst ratings

79%

of 34 ratings
Buy
79.4%
Hold
17.6%
Sell
2.9%

More LLY News

Nasdaq 1d
Lilly Launches Employer Connect Platform To Expand Access To Obesity Treatments

(RTTNews) - Eli Lilly and Company (LLY) on Thursday announced the launch of its Employer Connect platform, aimed at expanding access to obesity management treat...

Lilly Launches Employer Connect Platform To Expand Access To Obesity Treatments
Benzinga 1d
Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform

Eli Lilly and Company (NYSE:LLY) rolled out its new Employer Connect platform on Wednesday, targeting the roughly half of commercially insured American employee...

Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform
Simply Wall St 2d
Eli Lilly’s Nvidia AI Deal And Pipeline Progress Versus Rich Valuation

Eli Lilly (NYSE:LLY) has entered a $1 billion AI-focused drug discovery partnership with Nvidia, aimed at using advanced computing to support pharmaceutical R&D...

Eli Lilly’s Nvidia AI Deal And Pipeline Progress Versus Rich Valuation
24/7 Wall St. 2d
Forget AI. This Biotech Stock's Taking Off Right Now

Forget AI. This Biotech Stock’s Taking Off Right Now Quick Read Nvidia (NVDA) and Eli Lilly (LLY, down 7% YTD, forward P/E under 30x) in $1B partnership. Eli...

Forget AI. This Biotech Stock's Taking Off Right Now
TipRanks 2d
Lilly’s Tirzepatide Fasting Study Targets Safety Questions Around Obesity Blockbuster

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The study titled “A Study to Evaluate the Effect of Fasting Duration and Tempo...

TipRanks 3d
Ventyx Biosciences Shareholders Approve Merger With Eli Lilly

Ventyx Biosciences ( (VTYX) ) has issued an update. On January 7, 2026, Ventyx Biosciences, Inc. entered into a Merger Agreement with Eli Lilly and Company and...

The Motley Fool 3d
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Eli Lilly's (LLY 1.09%) big problem is its success in the GLP-1 drug space. Its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs grew sales by 99% a...

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.